Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of ONC201 in Neuroendocrine Tumors

NCT03034200 is registered in ClinicalTrials.gov with Peter Anderson as lead sponsor.

NCT NCT03034200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03034200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Lead sponsor
Peter Anderson
Phase
Phase 2
Overall status
Completed
Start date
August 2, 2017
Completion date
May 19, 2023
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic neuroendocrine tumor, recurrent neuroendocrine tumor